Antineoplastic agents 365. Dolastatin 10 SAR probes

George Pettit, Jayaram K. Srirangam, Jozsef Barkoczy, Michael D. Williams, Michael R. Boyd, Ernest Hamel, Robin Pettit, Fiona Hogan, Ruoli Bai, Jean Chapuis, Shane C. McAllister, Jean M. Schmidt

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The remarkable anticancer drug dolastatin 10 (1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials. Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide.

Original languageEnglish (US)
Pages (from-to)243-277
Number of pages35
JournalAnti-Cancer Drug Design
Volume13
Issue number4
StatePublished - Jun 1998

Fingerprint

dolastatin 10
Antineoplastic Agents
Tubulin
Hares
Indian Ocean
Peptides
Clinical Trials, Phase I
Vinblastine
Guanosine Triphosphate
Oceans and Seas
Polymerization
Cells
Cell Line
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antineoplastic agents
  • Dolastatin 10
  • Structural modifications

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Pettit, G., Srirangam, J. K., Barkoczy, J., Williams, M. D., Boyd, M. R., Hamel, E., ... Schmidt, J. M. (1998). Antineoplastic agents 365. Dolastatin 10 SAR probes. Anti-Cancer Drug Design, 13(4), 243-277.

Antineoplastic agents 365. Dolastatin 10 SAR probes. / Pettit, George; Srirangam, Jayaram K.; Barkoczy, Jozsef; Williams, Michael D.; Boyd, Michael R.; Hamel, Ernest; Pettit, Robin; Hogan, Fiona; Bai, Ruoli; Chapuis, Jean; McAllister, Shane C.; Schmidt, Jean M.

In: Anti-Cancer Drug Design, Vol. 13, No. 4, 06.1998, p. 243-277.

Research output: Contribution to journalArticle

Pettit, G, Srirangam, JK, Barkoczy, J, Williams, MD, Boyd, MR, Hamel, E, Pettit, R, Hogan, F, Bai, R, Chapuis, J, McAllister, SC & Schmidt, JM 1998, 'Antineoplastic agents 365. Dolastatin 10 SAR probes', Anti-Cancer Drug Design, vol. 13, no. 4, pp. 243-277.
Pettit G, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E et al. Antineoplastic agents 365. Dolastatin 10 SAR probes. Anti-Cancer Drug Design. 1998 Jun;13(4):243-277.
Pettit, George ; Srirangam, Jayaram K. ; Barkoczy, Jozsef ; Williams, Michael D. ; Boyd, Michael R. ; Hamel, Ernest ; Pettit, Robin ; Hogan, Fiona ; Bai, Ruoli ; Chapuis, Jean ; McAllister, Shane C. ; Schmidt, Jean M. / Antineoplastic agents 365. Dolastatin 10 SAR probes. In: Anti-Cancer Drug Design. 1998 ; Vol. 13, No. 4. pp. 243-277.
@article{8a9f4dc426ba48e1ba13961481e2c803,
title = "Antineoplastic agents 365. Dolastatin 10 SAR probes",
abstract = "The remarkable anticancer drug dolastatin 10 (1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials. Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide.",
keywords = "Antineoplastic agents, Dolastatin 10, Structural modifications",
author = "George Pettit and Srirangam, {Jayaram K.} and Jozsef Barkoczy and Williams, {Michael D.} and Boyd, {Michael R.} and Ernest Hamel and Robin Pettit and Fiona Hogan and Ruoli Bai and Jean Chapuis and McAllister, {Shane C.} and Schmidt, {Jean M.}",
year = "1998",
month = "6",
language = "English (US)",
volume = "13",
pages = "243--277",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "4",

}

TY - JOUR

T1 - Antineoplastic agents 365. Dolastatin 10 SAR probes

AU - Pettit, George

AU - Srirangam, Jayaram K.

AU - Barkoczy, Jozsef

AU - Williams, Michael D.

AU - Boyd, Michael R.

AU - Hamel, Ernest

AU - Pettit, Robin

AU - Hogan, Fiona

AU - Bai, Ruoli

AU - Chapuis, Jean

AU - McAllister, Shane C.

AU - Schmidt, Jean M.

PY - 1998/6

Y1 - 1998/6

N2 - The remarkable anticancer drug dolastatin 10 (1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials. Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide.

AB - The remarkable anticancer drug dolastatin 10 (1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials. Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide.

KW - Antineoplastic agents

KW - Dolastatin 10

KW - Structural modifications

UR - http://www.scopus.com/inward/record.url?scp=7144263706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144263706&partnerID=8YFLogxK

M3 - Article

C2 - 9627667

AN - SCOPUS:7144263706

VL - 13

SP - 243

EP - 277

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 4

ER -